MEMPHIS, Tenn., March 28, 2013 /PRNewswire/ -- MRI Interventions, Inc.'s (OTCBB: MRIC) innovative neurosurgical navigation platform, the ClearPoint® Neuro Intervention System, was featured on the Fox News Health website in a story published on March 25, 2013.
In her story titled "MRI-guided brain surgery easier on Parkinson's patients," Fox News reporter Laurie Tarkan recounts her interview with Dr. Hooman Azmi, director of the division of movement disorders at Hackensack University Medical Center in New Jersey, regarding his experience using the ClearPoint system in deep brain stimulation (DBS) surgeries. The story relates some of the drawbacks of the traditional DBS surgery and notes that surgeons have begun using the ClearPoint system to address those negative aspects of the procedure.
One of the more noticeable differences with the ClearPoint system, Tarkan points out, is that by using the interventional platform, surgeons are able to rely on real-time MRI guidance, rather than feedback from patients, to precisely place DBS leads at their target locations. This direct MRI guidance for surgeons means patients can sleep through a ClearPoint-navigated DBS procedure, unlike traditional methods of performing the surgery which generally require patients to remain awake through some of the operation. The ability to sleep through the procedure also allows patients to maintain their regular medication schedules, offering yet another level of comfort to a traditionally stressful operation.
To read the Fox News Health article in its entirety, please visit the following link:
About Deep Brain Stimulation (DBS)
Deep brain stimulation, or DBS, is a surgical option for treating the symptoms of Parkinson's disease. During the procedure, stimulating electrodes are placed in specific areas of the brain that control movement. Once the electrodes are in place, a pacemaker-like device is surgically implanted under the patient's collarbone that, when turned on, emits electric signals to the electrodes in order to stimulate the desired location in the patient's brain to relieve tremors and other symptoms of Parkinson's disease. DBS is often recommended only after medications become less effective due to the progression of the disease.
About MRI Interventions, Inc.
Founded in 1998, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared ClearPoint® system is designed to enable a range of minimally invasive procedures in the brain. MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint system. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.mriinterventions.com.
Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products; our ability to successfully expand our sales and marketing capabilities; our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, future products, including our current product candidates; availability of third party reimbursement; the sufficiency of our cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; and the impact of the commercial and credit environment on us and our customers and suppliers. More detailed information on these and additional factors that could affect MRI Interventions' actual results are described in MRI Interventions' filings with the Securities and Exchange Commission, including, without limitation, MRI Interventions' most recent annual report on Form 10-K. Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in MRI Interventions' expectations or any change in events, conditions or circumstances on which any such statements are based.
MRI Interventions, Inc.
David Carlson, CFO, 901-522-9300
SOURCE MRI Interventions, Inc.